Tokyo, Dec. 23 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060158) titled 'A comparative study of gemcitabine plus cisplatin and gemcitabine plus carboplatin in advanced urothelial carcinoma' on Dec. 22.
Study Type:
Observational
Primary Sponsor:
Institute - Tokyo Medical University Hachioji Medical Center
Condition:
Condition - Advanced urothelial carcinoma
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - The purpose of this study is to retrospectively compare the efficacy and prognosis of gemcitabine plus cisplatin and gemcitabine plus carboplatin as first line systemic chemotherapy for patients with advanced urothelial carcinoma, and to identify prognostic factors associated with overall survival.
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 20
years-old
Gender - Male and Female
Key inclusion criteria - - Histologically confirmed urothelial carcinoma
- Locally advanced or metastatic urothelial carcinoma
- Received gemcitabine plus cisplatin or gemcitabine plus carboplatin as first line systemic chemotherapy
Key exclusion criteria - - Patients who received initial systemic chemotherapy other than gemcitabine plus cisplatin or gemcitabine plus carboplatin
- Patients with active concomitant malignancies other than urothelial carcinoma
- Patients with insufficient clinical data prior to treatment initiation
Target Size - 86
Recruitment Status:
Recruitment status - Completed
Date of protocol fixation - 2014 Year 01 Month 01 Day
Date of IRB - 2025 Year 07 Month 31 Day
Anticipated trial start date - 2014 Year 01 Month 01 Day
Last follow-up date - 2024 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068803
Disclaimer: Curated by HT Syndication.
